Evidence map›Paper›PMID 38280377›Full record

ArticleCell reports. Medicine2024

Monoclonal antibody therapy protects nonhuman primates against mucosal exposure to Lassa virus.

Robert W Cross, Karla A Fenton, Courtney Woolsey, Abhishek N Prasad, Viktoriya Borisevich, Krystle N Agans, Daniel J Deer, Natalie S Dobias, Alyssa C Fears, Megan L Heinrich and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Robust polyfunctional CD8The Journal of general virology · 2025
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Lassa Fever: Critical Review and Prospects for Control.Tropical medicine and infectious disease · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Robert W CrossGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Karla A FentonGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Courtney WoolseyGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Abhishek N PrasadGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Viktoriya BorisevichGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Krystle N AgansGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Daniel J DeerGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Natalie S DobiasGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Alyssa C FearsGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Megan L HeinrichZalgen Labs, LLC, Frederick, MD, USA.
Joan B GeisbertGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Robert F GarryZalgen Labs, LLC, Frederick, MD, USA; Department of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, LA, USA.
Luis M BrancoZalgen Labs, LLC, Frederick, MD, USA.
Thomas W GeisbertGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA. Electronic address: twgeisbe@utmb.edu.
The University of Texas Medical Branch at Galveston · USZalgen (United States) · USTulane University · US

Funding

Regulatory Compliance Core - Galveston National Laboratory BSL4 OperationsUC7AI094660 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI Thomas Gary Ksiazek · 2011 to 2026
$208.8M
Specific and Broadly Active Monoclonal Antibody Therapeutics Against The FilovirusesU19AI142790 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI SAPHIRE, ERICA OLLMANN · 2019 to 2023
$40.0M
Technology CoreU19AI135995 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI Kristian Graugaard Andersen · 2018 to 2026
$32.0M
Preclinical evaluation of a potent Lassa fever immunotherapeutic antibody cocktailR01AI132223 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI GARRY, ROBERT F · 2017 to 2021
$5.7M
NIAID NIH HHS R01 AI132223NIAID NIH HHS U19 AI135995NIAID NIH HHS U19 AI142790NIAID NIH HHS UC7 AI094660
6 · The paper itself

Abstract

Lassa fever (LF) is an acute viral illness that causes thousands of deaths annually in West Africa. There are currently no Lassa virus (LASV) vaccines or antivirals approved for human use. Recently, we showed that combinations of broadly neutralizing human monoclonal antibodies (BNhuMAbs) known as Arevirumab-2 or Arevirumab-3 protected up to 100% of cynomolgus macaques against challenge with diverse lineages of LASV when treatment was initiated at advanced stages of disease. This previous work assessed efficacy against parenteral exposure. However, transmission of LASV to humans occurs primarily by mucosal exposure to virus shed from Mastomys rodents. Here, we describe the development of a lethal intranasal exposure macaque model of LF. This model is employed to show that Arevirumab cocktails rescue 100% of macaques from lethal LASV infection when treatment is initiated 8 days after LASV exposure. Our work demonstrates BNhuMAbs have utility in treating LASV infection acquired through mucosal exposure.

Indexed as

Lassa FeverLassa virusAnimalsAntibodies, MonoclonalHumansImmunotherapyMacaca fascicularisAntibodies, Monoclonalanimal modelantibodyArenavirushemorrhagic feverintranasalLassa virusmonoclonalmucosalneutralizingnonhuman primate

Identifiers

PMID38280377
PMCPMC10897540
OpenAlexW4391253046

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.